Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 3/20 | 0.44 |
| ▸ | F3 | P13726 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694673 | 1.00 | FAAH (0.50) | FAAHALDH1A1CNR1CNR2DGKA | |
| SCHEMBL12664404 | 1.00 | FAAH (0.50) | FAAHALDH1A1CNR1CNR2DGKA | |
| SCHEMBL12735352 | 1.00 | FAAH (0.50) | FAAHALDH1A1CNR1CNR2DGKA | |
| SCHEMBL254523 | 0.95 | DGKA (0.49) | FAAHALDH1A1CNR1CNR2DGKA | |
| SCHEMBL254521 | 0.95 | DGKA (0.49) | FAAHALDH1A1CNR1CNR2DGKA | |
| SCHEMBL26835765 | 0.87 | KDM4E (0.46) | ALDH1A1CNR1F7F3PPARG | |
| SCHEMBL26835759 | 0.87 | KDM4E (0.46) | ALDH1A1CNR1F7F3PPARG | |
| SCHEMBL26858557 | 0.87 | KDM4E (0.46) | ALDH1A1CNR1F7F3PPARG | |
| SCHEMBL31285101 | 0.87 | KDM4E (0.46) | ALDH1A1CNR1F7F3PPARG | |
| SCHEMBL26835758 | 0.87 | KDM4E (0.46) | ALDH1A1CNR1F7F3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2314 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235559-A1 | GENE EDITING REPORTER SYSTEM AND GUIDE RNA AND COMPOSITION RELATED THERETO; COMPOSITION AND METHOD FOR KNOCKING OUT DNA WITH MORE THAN TWO GRNAS; GENE EDITING IN THE EYE; AND GENE EDITING USING BASE EDITORS | Incisive Genetics Inc. (CA) | 2025-07-24 | — | — | US | claimed |
| EP-4577658-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE AND COMPOSITIONS AND METHODS FOR DISRUPTING GENES AND GENE SEGMENTS | INCISIVE GENETICS, INC. (CA) | 2025-07-02 | — | — | EP | claimed |
| WO-2025103414-A1 | PREPARATION METHOD FOR AND USE OF LIPID NANOPARTICLES | 上海瑞宏迪医药有限公司 | 2025-05-22 | — | — | WO | claimed |
| WO-2025024500-A1 | METHODS AND SYSTEMS FOR TRANSDERMAL IMMUNOTHERAPY | Passport Technologies, Inc. (US) | 2025-01-30 | — | — | WO | claimed |
| EP-4463555-A1 | GENE EDITING REPORTER SYSTEM AND GUIDE RNA AND COMPOSITION RELATED THERETO; COMPOSITION AND METHOD FOR KNOCKING OUT DNA WITH MORE THAN TWO GRNAS; GENE EDITING IN THE EYE; AND GENE EDITING USING BASE EDITORS | INCISIVE GENETICS, INC. (CA) | 2024-11-20 | — | — | EP | claimed |
| US-20240358652-A1 | LIPID NANOPARTICLE FORMULATIONS | MONASH UNIVERSITY (AU) | 2024-10-31 | — | — | US | claimed |
| EP-4409004-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE | The University of British Columbia (CA) | 2024-08-07 | — | — | EP | claimed |
| EP-4387657-A1 | LIPID NANOPARTICLE FORMULATIONS | Monash University (AU) | 2024-06-26 | — | — | EP | claimed |
| US-20240175012-A1 | GUIDE RNAS AND COMPOSITIONS FOR EDITING HUNTINGTIN GENE, AND METHODS RELATED THERETO | UNIV BRITISH COLUMBIA (CA) | 2024-05-30 | — | — | US | claimed |
| US-20240175024-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ALNYLAM PHARMACEUTICALS, INC. | 2024-05-30 | — | — | US | claimed |
| WO-2022115739-A1 | — | — | 2022-06-02 | — | — | WO | claimed |
| US-20210388355-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | BANK OF AMERICA, N.A. | 2021-12-16 | — | — | US | claimed |
| US-20190284557-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ALNYLAM PHARMACEUTICALS INC (US) | 2019-09-19 | — | — | US | claimed |
| US-10246708-B2 | Dosages and methods for delivering lipid formulated nucleic acid molecules | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | claimed |
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-11-01 | — | — | US | claimed |
| EP-3368089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-09-05 | — | — | EP | claimed |
| WO-2017075038-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | RANA THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | claimed |
| US-20160122759-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-05 | — | — | US | claimed |
| EP-2994167-A2 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | Alnylam Pharmaceuticals, Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| WO-2014182661-A2 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ALNYLAM PHARMACEUTICALS, INC (US) | 2014-11-13 | — | — | WO | claimed |